TAK
Takeda Pharmaceutical Company Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · JP
$19.95
−1.02%Year over year
Reported trailing growth
- Revenue
- +4.0%
- EBITDA
- +8.3%
- EBIT
- +41.9%
- EPS
- +31.9%
- Free cash flow
- -36.6%
- Operating cash flow
- -13.5%
Forward estimates
Based on analyst estimates
- Revenue
- +0.4%
- EBITDA
- +10.2%
- EPS
- +108.9%
Three-year CAGR
- Revenue
- +5.9%
- EBITDA
- +2.3%
- EBIT
- +5.3%
- Net income
- -13.8%
- EPS
- -14.5%
- Free cash flow
- +22.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026